The financial assistance the Patient Access Network (PAN) Foundation provides patients is an important part of the safety net and happens in a way that doesn't influence how patients get treatment or what products they use, explained Daniel J. Klein, president and CEO of PAN.
The financial assistance the Patient Access Network (PAN) Foundation provides patients is an important part of the safety net and happens in a way that doesn't influence how patients get treatment or what products they use, explained Daniel J. Klein, president and CEO of PAN.
Transcript (modified)
How does the Patient Access Network (PAN) reduce barriers to innovative care?
PAN is a charitable copay foundation. We operate under rules established by the Office of the Inspector General at HHS, and basically these rules are designed to ensure that there’s no inappropriate influence, coming from the people who donate to PAN, over the type of treatment that the patient receives. Most of our donations are from drug manufacturers and the OIG’s rules essentially require us to be agnostic about the treatments people can receive and get assistance with.
So when a manufacturer donates money to us we’re using that money to provide assistance for any of the treatments that a patient may need in a given disease area, which would include all of the generic medications, all of the other brand-name medications made by any manufacturers. We think that’s a unique and important part of the safety net, that within the rules that have been established by the OIG we’re able to provide assistance in a way that doesn’t influence how patients are getting their treatment or what products they’re using.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More